Novo Nordisk's Rybelsus Shows Promise in Reducing Cardiovascular Events

Copenhagen, Saturday, 29 March 2025.
Novo Nordisk’s Rybelsus reduced major cardiovascular events by 14% in type 2 diabetes patients, as revealed in the SOUL trial at ACC 2025.